Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • emc易倍官网入口Media Updates
    • emc易倍官网入口Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • emc易倍官网入口Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • emc易倍官网入口Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • emc易倍官网入口Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • emc易倍官网入口Our Locations
    • Report Side Effects
    • emc易倍官网入口Subscribe
  • Press shift tab to select search category
    Loading...
  • English  EN     Fran?ais  FR     EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • emc易倍官网入口Middle East & Africa
    • emc易倍官网入口 Brazil
    • Canada
    • United States
    • Mexico
    • Colombia
    • emc易倍官网入口 Australia
    • China
    • Singapore
    • emc易倍官网入口 South Korea
    • Japan
    • emc易倍官网入口 Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • emc易倍官网入口 Nordics
    • emc易倍官网入口 Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • emc易倍官网入口 Russia
    • emc易倍官网入口 Czech Republic
    • emc易倍官网入口 Romania
    • Hungary
    • Slovakia
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • emc易倍官网入口Leadership
    • History
    • emc易倍官网入口Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • emc易倍官网入口Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • emc易倍官网入口Clinical Trials
      • Lay Summaries
      • emc易倍官网入口Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • emc易倍官网入口Patients
    • emc易倍官网入口Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • emc易倍官网入口Collaborate with us
  • Stories
  1. Home
  2. emc易倍官网入口Newsroom – Newsroom – Subscribe to Ipsen News

emc易倍官网入口

IPN price

€166.00

 €3.40 (2.09%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • emc易倍官网入口Cookie Policy
  • Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?







2026-08-26 9:51:09